| [1] |
Wang W, Li G. Incidence and prognostic factors of hepatoid adenocarcinoma: a population-based analysis[J]. Transl Cancer Res, 2020, 9(9): 5401-5410. DOI: 10.21037/tcr-20-1126.
pmid: 35117905
|
| [2] |
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition)[J]. Gastric Cancer, 2021, 24(1): 1-21. DOI: 10.1007/s10120-020-01042-y.
|
| [3] |
Chen X, Li AQ, Wang QX, et al. Hepatoid adenocarcinoma in the peritoneal cavity: two case reports[J]. Medicine (Baltimore), 2019, 98(5): e14226. DOI: 10.1097/MD.0000000000014226.
|
| [4] |
Zhou K, Wang QN, Ao S, et al. The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis[J]. BMC Cancer, 2020, 20(1): 671. DOI: 10.1186/s12885-020-07031-9.
pmid: 32680468
|
| [5] |
Zhang ZR, Wu J, Li HW, et al. Hepatoid adenocarcinoma of the stomach: thirteen case reports and review of literature[J]. World J Clin Cases, 2020, 8(6): 1164-1171. DOI: 10.12998/wjcc.v8.i6. 1164.
|
| [6] |
He F, Fu Y, Sun Q, et al. Integrated clinicopathological and immunohistochemical analysis of gastric adenocarcinoma with hepatoid differentiation: an exploration of histogenesis, molecular characteristics, and prognostic markers[J]. Hum Pathol, 2021, 115: 37-46. DOI: 10.1016/j.humpath.2021.02.003.
|
| [7] |
Søreide JA. Therapeutic approaches to gastric hepatoid adenocarcinoma: current perspectives[J]. Ther Clin Risk Manag, 2019, 15: 1469-1477. DOI: 10.2147/TCRM.S204303.
|
| [8] |
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1224-1235. DOI: 10.1016/S1470-2045(14)70420-6.
pmid: 25240821
|
| [9] |
Søreide JA. Therapeutic approaches to gastric hepatoid adenocarcinoma: current perspectives[J]. Ther Clin Risk Manag, 2019, 15: 1469-1477. DOI: 10.2147/TCRM.S204303.
|
| [10] |
Baek SK, Han SW, Oh DY, et al. Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer[J]. BMC Gastroenterol, 2011, 11: 56. DOI: 10.1186/1471-230X-11-56.
pmid: 21592404
|
| [11] |
Yoshizawa J, Ishizone S, Ikeyama M, et al. Gastric hepatoid adenocarcinoma resulting in a spontaneous gastric perforation: a case report and review of the literature[J]. BMC Cancer, 2017, 17(1): 368. DOI: 10.1186/s12885-017-3357-7.
pmid: 28545511
|
| [12] |
Doi Y, Takii Y, Mitsugi K, et al. The Effectiveness of hepatic arterial infusion chemotherapy with 5-fluorouracil/cisplatin and systemic chemotherapy with ramucirumab in alpha-fetoprotein-producing gastric cancer with multiple liver metastases[J]. Case Rep Oncol Med, 2018, 2018: 5402313. DOI: 10.1155/2018/5402313.
|
| [13] |
Li W, Li Q, Yu YY, et al. Effect of immune checkpoint inhibitors plus chemotherapy on advanced gastric cancer patients with elevated serum AFP or hepatoid adenocarcinoma[J]. Cancer Manag Res, 2020, 12: 11113-11119. DOI: 10.2147/CMAR.S276969.
pmid: 33173344
|
| [14] |
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742):687-697. DOI: 10.1016/S0140-6736(10)61121-X.
|
| [15] |
Arakawa Y, Tamura M, Aiba K, et al. Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: a case report[J]. Oncol Lett, 2017, 14(3): 3039-3042. DOI: 10.3892/ol.2017.6514.
pmid: 28928842
|
| [16] |
Lin JX, Wang ZK, Hong QQ, et al. Assessment of clinicopathological characteristics and development of an individualized prognostic model for patients with hepatoid adenocarcinoma of the stomach[J]. JAMA Netw Open, 2021, 4(10): e2128217. DOI: 10.1001/jamanetworkopen.2021.28217.
|
| [17] |
Kamei SG, Kono K, Amemiya H, et al. Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein[J]. J Gastroenterol, 2003, 38(6): 540-547. DOI: 10.1007/s00535-002-1099-y.
pmid: 12825129
|
| [18] |
Mei Y, Li M, Wen J, et al. Single-cell characteristics and malignancy regulation of alpha-fetoprotein-producing gastric cancer[J]. Cancer Med, 2023, 12(10): 12018-12033. DOI: 10.1002/cam4.5883.
|
| [19] |
Fang YU, Wang L, Yang N, et al. Successful multimodal therapy for an α-fetoprotein-producing gastric cancer patient with simultaneous liver metastases[J]. Oncol Lett, 2015, 10(5): 3021-3025. DOI: 10.3892/ol.2015.3731.
pmid: 26722283
|
| [20] |
Xia R, Zhou Y, Wang Y, et al. Hepatoid adenocarcinoma of the stomach: current perspectives and new developments[J]. Front Oncol, 2021, 11: 633916. DOI: 10.3389/fonc.2021.633916.
|
| [21] |
Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice[J]. Science, 1997, 276(5317): 1423-1425. DOI: 10.1126/science.276.5317.1423.
pmid: 9162011
|
| [22] |
Xu JM, Shen L, Zhou ZW, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(11): 1500-1512. DOI: 10.1016/S1470-2045(20)30496-4.
pmid: 32966811
|
| [23] |
Cao YS, Lu M, Sun Y, et al. Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial[J]. J Cancer Res Clin Oncol, 2023, 149(2): 779-789. DOI: 10.1007/s00432-021-03898-8.
|
| [24] |
Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy[J]. Cell, 2017, 168(4): 707-723. DOI: 10.1016/j.cell.2017.01.017.
pmid: 28187290
|
| [25] |
Ho WJ, Jaffee EM. Macrophage-targeting by CSF1/1R blockade in pancreatic cancers[J]. Cancer Res, 2021, 81(24): 6071-6073. DOI: 10.1158/0008-5472.CAN-21-3603.
pmid: 34911778
|
